



Helsingborg October 14, 2024

## Press release

# Aqilion presents new results from the AQ312 program (oral Ahr agonist) during UEG Week in Vienna

**AQILION AB (publ) is developing the anti-inflammatory drug candidate AQ312 for the treatment of ulcerative colitis, and presents new results from the Aqilion preclinical development program at the United European Gastroenterology (UEG) Week in Vienna.**

Wayne Russell, Senior Director Translational Biology and Innovation, presents new preclinical data describing the drug candidate AQ312 in several gastrointestinal disease models. The presentation will take place during UEG Week 2024 in Vienna on October 12-15 (<https://ueg.eu/week>).

Aqilion is developing the drug candidate AQ312, an agonist of the nuclear hormone receptor called Arylhydrocarbon Receptor(AhR), for the treatment of ulcerative colitis.

Activation of AhR restores immune system homeostasis via regulatory T-cells. AQ312 stimulates the activation of regulatory T-cells locally in the gut, which is a natural anti-inflammatory mechanism. The activated regulatory T-cells suppress effector T-cells, which drive the destructive inflammation of ulcerous colitis. Additionally, the Ahr mechanism accelerates healing of the intestinal epithelium, which may further enhance the therapeutic efficacy.

AQ312 offers a new therapeutic mechanism with potential for a step change in therapeutic efficacy in ulcerative colitis.

### **For more information, please contact:**

Sarah Fredriksson, CEO, AQILION AB, + 46 (0)70 261 4575, [sarah.fredriksson@aqilion.com](mailto:sarah.fredriksson@aqilion.com)

### **About Aqilion**

Aqilion is a biotech company that focuses on developing innovative new treatments for diseases caused by chronic inflammation and dysfunctional immune reactions such as autoimmune diseases.

We identify innovative ideas that could potentially lead to new medications and refine them into commercially interesting projects. The innovation approach is based on solid scientific grounds, in disease areas where we, with reasonable assumptions, can understand the underlying biology, clinical relevance of the mechanism, potential patient benefit and the likelihood for finding a partner.

The company is mainly active in the early phases of drug discovery, from idea to proof-of-concept in clinical trials. Aqilion executes its development programs in a partly virtual organization in close collaboration with selected partners, with specific expertise in drug development. AQILION AB (publ) is a Swedish public limited company headquartered in Helsingborg, Sweden. [www.aqilion.com](http://www.aqilion.com)